Researchers led by Prof. Johan Thevelein (VIB-KU Leuven Center for Microbiology) have discovered that Saccharomyces boulardii, a yeast with probiotic properties, produces uniquely excessive amounts of acetic acid, the main component of vinegar. They were also able to find the genetic basis for this trait, which allowed them to modify the acetic acid production of the yeast. If this unique S. boulardii trait can be further validated to have a probiotic effect in animal models, these results could provide the first genetic basis for S. boulardii’s unique probiotic potency. The study is published in
A tale of mysterious yeast
In 1923, the French scientist Henri Boulard isolated a mysterious yeast strain from lychees in South East Asia. This yeast turned out to have unexpected and potent probiotic properties. This yeast, called Saccharomyces boulardii, has since been commercialized for treatment of diarrhea and other intestinal diseases. It is now sold in pharmacies all over the world under a wide range of trade names.
Recent whole-genome DNA sequence analysis showed that S. boulardii is closely related to the much better-known Saccharomyces cerevisiae, the yeast species of which different varieties are commonly used in baking, beer brewing, wine making, bioethanol production, etc. The DNA sequence of these two yeasts is actually so similar that S. boulardii is no longer considered as a separate species but as a variety of S. cerevisiae. Why this S. boulardii yeast has been so successful as probiotic, as opposed to the common S. cerevisiae yeasts, has remained a complete mystery.
The vinegar mutations
The team led by Prof. Johan Thevelein (VIB-KU Leuven) found that the production of acetic acid, the main ingredient of vinegar, is a distinguishable feature of Saccharomyces boulardii. Acetic acid is a well-known preservative and strongly inhibits the growth of all microorganisms. But how does S. boulardii produce such large amounts of acetic acid?
Time for a genetic investigation, as Prof. Thevelein explains: “We were able to find two unique mutations in S. boulardii that are responsible for the production of acetic acid. These mutations can act as a genetic ‘fingerprint’ that allows us to distinguish between these two types of yeast and allow the isolation and identification of new S. boulardii strains from nature.”
Based on this knowledge, the researchers were able to implement CRISPR/Cas genome editing to abolish acetic acid production completely as well as switch high into very high acetic acid producers and vice versa. These modified yeast strains can now be used to test the importance of the acetic acid production for the probiotic power of S. boulardii in laboratory animals, which, in turn, may pave the path towards improved treatments for intestinal diseases.
Unique genetic basis of the distinct antibiotic potency of high acetic acid production in the probiotic yeast Saccharomyces cerevisiae var. boulardii, Offei B., P. Vandecruys, S. De Graeve, M.R. Foulquié-Moreno and J.M. Thevelein,
This work was supported by an SBO grant (IWT 90043) from IWT-Flanders (now VLAIO-Flanders) and the EC 7th Framework program (CORNUCOPIA project) to JMT.
This research is part of a Grand Challenges project. The VIB Grand Challenges Program has been launched to significantly increase the societal impact of VIB, with support from the Flemish Government.
Questions from patients
A breakthrough in research is not the same as a breakthrough in medicine. The realizations of VIB researchers can form the basis of new therapies, but the development path still takes years. This can raise a lot of questions. That is why we ask you to please refer questions in your report or article to the email address that VIB makes available for this purpose:
. Everyone can submit questions concerning this and other medically-oriented research directly to VIB via this address.
This part of information is sourced from https://www.eurekalert.org/pub_releases/2019-08/vfi-upy083019.php
Manon Van Nuffel